Program
Anti-PD-L1 Antibody-drug Conjugate HLX43
Also written as “HLX43”, “HLX43 DOSE 1” and “HLX43 DOSE 2”.
In Fosun Pharma’s pipeline, PD-L1 ADC
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Neoplasms · Uterine Cervical Neoplasms · Triple Negative Breast Neoplasms · Breast Neoplasms, led by Fosun Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 1717 open or running | phase 3since Mar 5, 2026 | Oct 30, 2023 | Nov 22, 2026phase 2 · NCT06839066 |
- Named in Fosun Pharma’s own pipeline as
HLX43 (PD-L1 ADC)
, phase 2, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2023First study: phase 1 study in Advanced/Metastatic Malignant Solid TumorsFirst studyNCT06115642 · 367 planned · United States, China, Japan
- Dec 16, 2024Phase 2 study in Carcinoma, HepatocellularNCT06742892 · 90 planned · China
- Jan 7, 20253 phase 2 studiesNCT06769152, NCT06769113, NCT06848699
- Feb 18, 20252 phase 2 studiesNCT06839066, NCT06857279
- Mar 26, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06907615 · 243 planned · United States, China
- Jul 30, 2025Phase 2 study in Colorectal NeoplasmsNCT07106892 · 60 planned · China
- Aug 4, 2025Phase 2 study in Gastric or Gastroesophageal Junction AdenocarcinomaNCT07115485 · 60 planned · China
- Nov 19, 20253 phase 2 studiesNCT07253142, NCT07301229, NCT07269782
- Jan 14, 2026Phase 2 study in Colonic NeoplasmsNCT07358585 · 126 planned · China
- Mar 5, 2026Phase 3 study in Advanced or Metastatic Squamous Non-Small Cell Lung CancerPhase 3 reachedNCT07459751 · 706 planned · China
- Mar 5, 20262 phase 2 studies in Breast NeoplasmsNCT07459738, NCT07487519
- Oct 13, 2026Primary completion moved from 2026-06-30 to 2026-12-30Date moved laterphase 1 · +6 months · NCT06115642
Ahead
- Nov 22, 2026Primary completion: phase 2 study in Nasopharyngeal CarcinomaNCT06839066
- Dec 30, 2026Primary completion: phase 2 study in Breast NeoplasmsNCT07459738
- Dec 30, 2026Primary completion: phase 2 study in Colorectal NeoplasmsNCT07106892
- Dec 30, 2026Primary completion: phase 1 study in Advanced/Metastatic Malignant Solid TumorsNCT06115642
TargetBeta
“PD-L1 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07487519Breast Neoplasms · China | 2 | Not yet recruiting | May 15, 2027 | 180 |
| NCT07459751Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · China | 3 | Recruiting | Jan 15, 2030 | 706 |
| NCT07459738Breast Neoplasms | 2 | Not yet recruiting | Dec 30, 2026 | 60 |
| NCT07358585Colonic Neoplasms · China | 2 | Not yet recruiting | Jul 28, 2027 | 126 |
| NCT07269782Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jul 10, 2026 | 60 |
| NCT07301229Pancreatic Ductal Adenocarcinoma (PDAC) | 2 | Not yet recruiting | Feb 21, 2028 | 100 |
| NCT07253142Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 18, 2027 | 120 |
| NCT07115485Gastric or Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Aug 30, 2027 | 60 |
| NCT07106892Colorectal Neoplasms · China | 2 | Recruiting | Dec 30, 2026 | 60 |
| NCT06907615Carcinoma, Non-Small-Cell Lung · United States, China | 2 | Recruiting | Apr 20, 2028 | 243 |
| NCT06857279Carcinoma of Head and/or Neck · China | 2 | Recruiting | Dec 30, 2027 | 167 |
| NCT06839066Nasopharyngeal Carcinoma · China | 2 | Recruiting | Nov 22, 2026 | 70 |
| NCT06848699Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Oct 30, 2026 | 105 |
| NCT06769152Uterine Cervical Neoplasms · China | 2 | Recruiting | Dec 31, 2026 | 190 |
| NCT06769113Esophageal Neoplasms · China | 2 | Recruiting | Oct 31, 2026 | 102 |
| NCT06742892Carcinoma, Hepatocellular · China | 2 | Recruiting | Oct 31, 2026 | 90 |
| NCT06115642Advanced/Metastatic Malignant Solid Tumors · United States, China, Japan | 1 | By invitation | Dec 30, 2026 | 367 |
How it is read
Names in the registry
- “HLX43”, 5 entries
- “HLX43 DOSE 1”, 5 entries
- “HLX43 DOSE 2”, 5 entries
- “HLX43 DOSE 3”, 4 entries
- “HLX43 dose 1”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Esophageal Neoplasms, 1 study
- Uterine Cervical Neoplasms, 1 study
- Triple Negative Breast Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.